Morning Briefing
Summaries of health policy coverage from major news organizations
Activist Investor Icahn Drops Opposition To Cigna-Express Scripts Deal After Advisory Firms Signal Their Support
Activist investor Carl Icahn said on Monday that he no longer intended to solicit proxies to vote against the $52 billion Cigna-Express Scripts deal, a turn around from his position last week when he urged the health insurer's shareholders to vote against it. Icahn's comments come after proxy advisory firms Glass Lewis & Co and Institutional Shareholder Services Inc (ISS), as well as hedge fund Glenview Capital Management, extended their support for the deal. (8/13)
Cigna has said Mr. Icahn doesn’t understand the dynamics of health care and appeared to be betting against the deal for a profit. It called his opposition “misguided and shortsighted� in a statement last week. Mr. Icahn said in his statement that he informed the Securities and Exchange Commission he will no longer solicit proxies to vote against the transaction. (Lombardo, 8/13)
“In light of the ISS and Glass Lewis recommendations in favor of the Cigna/Express Scripts transaction and the significant stockholder overlap between the companies, we have informed the SEC we no longer intend to solicit proxies to vote against the transaction,� Icahn said Monday in a statement. (Deveau, 8/13)